BACKGROUND - Understanding predictors for the recovery of erectile function (EF) after nerve-sparing radical prostatectomy (nsRP) might help clinicians and patients in preoperative counseling and expectation management of EF rehabilitation strategies.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
OBJECTIVE - To describe the effect of potential predictors on EF recovery after nsRP by post hoc decision-tree modeling of data from A Study of Tadalafil After Radical Prostatectomy (REACTT).
DESIGN, SETTING, AND PARTICIPANTS - Randomized double-blind double-dummy placebo-controlled trial in 423 men aged
INTERVENTION - Postsurgery 1:1:1 randomization to 9-mo double-blind treatment with tadalafil 5mg once a day (OaD), tadalafil 20mg on demand, or placebo, followed by a 6-wk drug-free-washout, and a 3-mo open-label tadalafil OaD treatment.
OUTCOME MEASURES AND STATISTICAL ANALYSIS - Three decision-tree models, using the International Index of Erectile Function-Erectile Function (IIEF-EF) domain score at the end of double-blind treatment, washout, and open-label treatment as response variable. Each model evaluated the association between potential predictors: presurgery IIEF domain and IIEF single-item scores, surgical approach, nerve-sparing score (NSS), and postsurgery randomized treatment group.
RESULTS AND LIMITATIONS - The first decision-tree model (n=422, intention-to-treat population) identified high presurgery sexual desire (IIEF item 12: ≥3.5 and <3.5) as the key predictor for IIEF-EF at the end of double-blind treatment (mean IIEF-EF: 14.9 and 11.1), followed by high confidence to get and maintain an erection (IIEF item 15: ≥3.5 and <3.5; IIEF-EF: 15.4 and 7.1). For patients meeting these criteria, additional non-IIEF-related predictors included robot-assisted laparoscopic surgery (yes or no; IIEF-EF: 19.3 and 12.6), quality of nerve sparing (NSS:
CONCLUSIONS - Exploratory decision-tree analyses identified high presurgery sexual desire, confidence, and intercourse satisfaction as key predictors for EF recovery. Patients meeting these criteria might benefit the most from conserving surgery and early postsurgery EF rehabilitation. Strategies for improving EF after surgery should be discussed preoperatively with all patients; this information may support expectation management for functional recovery on an individual patient level.
PATIENT SUMMARY - Understanding how patient characteristics and different treatment options affect the recovery of erectile function (EF) after radical surgery for prostate cancer might help physicians select the optimal treatment for their patients. This analysis of data from a clinical trial suggested that high presurgery sexual desire, sexual confidence, and intercourse satisfaction are key factors predicting EF recovery. Patients meeting these criteria might benefit the most from conserving surgery (robot-assisted surgery, perfect nerve sparing) and postsurgery medical rehabilitation of EF.
TRIAL REGISTRATION - ClinicalTrials.gov, NCT01026818.
European urology. 2016 Mar 03 [Epub ahead of print]
Francesco Montorsi, Matthias Oelke, Carsten Henneges, Gerald Brock, Andrea Salonia, Gianluca d'Anzeo, Andrea Rossi, John P Mulhall, Hartwig Büttner
Department of Urology, Vita Salute San Raffaele University, Milan, Italy. Department of Urology and Urological Oncology, Hanover Medical School, Hanover, Germany., Global Statistical Sciences, EU Statistics, Lilly Deutschland GmbH, Bad Homburg, Germany., Department of Surgery, Division of Urology, University of Western Ontario, London, Ontario, Canada., Department of Urology, Vita Salute San Raffaele University, Milan, Italy., Therapeutic Area Men's Health, Eli Lilly SpA, Florence, Italy., Therapeutic Area Men's Health, Eli Lilly SpA, Florence, Italy., Memorial Sloan Kettering Cancer Center, New York, NY, USA., Biomedicines BU, Lilly Deutschland GmbH, Bad Homburg, Germany.